These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 31858575)
1. Budesonide and Poractant Alfa prevent bronchopulmonary dysplasia via triggering SIRT1 signaling pathway. Du FL; Dong WB; Zhang C; Li QP; Kang L; Lei XP; Guo L; Zhai XS Eur Rev Med Pharmacol Sci; 2019 Dec; 23(24):11032-11042. PubMed ID: 31858575 [TBL] [Abstract][Full Text] [Related]
2. [Efficacy analysis of different pulmonary surfactants in premature infants with respiratory distress syndrome]. Xu H; Xu P Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Feb; 33(2):174-179. PubMed ID: 33729136 [TBL] [Abstract][Full Text] [Related]
3. [Clinical efficacy of pulmonary surfactant combined with budesonide for preventing bronchopulmonary dysplasia in very low birth weight infants]. Pan J; Chen MW; Ni WQ; Fang T; Zhang H; Chen Y; Pan JH Zhongguo Dang Dai Er Ke Za Zhi; 2017 Feb; 19(2):137-141. PubMed ID: 28202108 [TBL] [Abstract][Full Text] [Related]
4. Role of the SENP1-SIRT1 pathway in hyperoxia-induced alveolar epithelial cell injury. Dong W; Zhu X; Liu X; Zhao X; Lei X; Kang L; Liu L Free Radic Biol Med; 2021 Sep; 173():142-150. PubMed ID: 34311030 [TBL] [Abstract][Full Text] [Related]
5. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Sinha SK; Lacaze-Masmonteil T; Valls i Soler A; Wiswell TE; Gadzinowski J; Hajdu J; Bernstein G; Sanchez-Luna M; Segal R; Schaber CJ; Massaro J; d'Agostino R; Pediatrics; 2005 Apr; 115(4):1030-8. PubMed ID: 15805381 [TBL] [Abstract][Full Text] [Related]
6. [Efficacy of different preparations of budesonide combined with pulmonary surfactant in the treatment of neonatal respiratory distress syndrome: a comparative analysis]. Ke H; Li ZK; Yu XP; Guo JZ Zhongguo Dang Dai Er Ke Za Zhi; 2016 May; 18(5):400-4. PubMed ID: 27165587 [TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo characterization of poractant alfa supplemented with budesonide for safe and effective intratracheal administration. Ricci F; Catozzi C; Ravanetti F; Murgia X; D'Aló F; Macchidani N; Sgarbi E; Di Lallo V; Saccani F; Pertile M; Cacchioli A; Catinella S; Villetti G; Civelli M; Amadei F; Stellari FF; Pioselli B; Salomone F Pediatr Res; 2017 Dec; 82(6):1056-1063. PubMed ID: 28723887 [TBL] [Abstract][Full Text] [Related]
9. [Decreased SIRT1 expression is related to bronchopulmonary dysplasia in premature infants after oxygen exposure]. Tan F; Dong W; Lei X; Liu X; Li Q; Kang L; Zhao S; Zhang C Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Dec; 32(12):1632-1635. PubMed ID: 27916095 [TBL] [Abstract][Full Text] [Related]
10. A randomized, controlled trial of poractant alfa versus beractant in the treatment of preterm infants with respiratory distress syndrome. Dizdar EA; Sari FN; Aydemir C; Oguz SS; Erdeve O; Uras N; Dilmen U Am J Perinatol; 2012 Feb; 29(2):95-100. PubMed ID: 22105435 [TBL] [Abstract][Full Text] [Related]
11. Attenuated SUMOylation of sirtuin 1 in premature neonates with bronchopulmonary dysplasia. Tan F; Dong W; Lei X; Liu X; Li Q; Kang L; Zhao S; Zhang C Mol Med Rep; 2018 Jan; 17(1):1283-1288. PubMed ID: 29115559 [TBL] [Abstract][Full Text] [Related]
12. Intratracheal Administration of Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia. Yeh TF; Chen CM; Wu SY; Husan Z; Li TC; Hsieh WS; Tsai CH; Lin HC Am J Respir Crit Care Med; 2016 Jan; 193(1):86-95. PubMed ID: 26351971 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of surfactant-TA, calfactant and poractant alfa for preterm infants with respiratory distress syndrome: a retrospective study. Jeon GW; Oh M; Sin JB Yonsei Med J; 2015 Mar; 56(2):433-9. PubMed ID: 25683992 [TBL] [Abstract][Full Text] [Related]
14. Early Intratracheal Administration of Corticosteroid and Pulmonary Surfactant for Preventing Bronchopulmonary Dysplasia in Preterm Infants with Neonatal Respiratory Distress Syndrome: A Meta-analysis. Zhong YY; Li JC; Liu YL; Zhao XB; Male M; Song DK; Bai Y Curr Med Sci; 2019 Jun; 39(3):493-499. PubMed ID: 31209823 [TBL] [Abstract][Full Text] [Related]
15. Effect of two different early rescue surfactant treatments on mortality in preterm infants with respiratory distress syndrome. Kadıoğlu Şimşek G; Kanmaz Kutman HG; Canpolat FE; Oğuz ŞS Clin Respir J; 2020 Mar; 14(3):285-290. PubMed ID: 31814293 [TBL] [Abstract][Full Text] [Related]
16. Inhalation or instillation of steroids for the prevention of bronchopulmonary dysplasia. Bassler D Neonatology; 2015; 107(4):358-9. PubMed ID: 26044104 [TBL] [Abstract][Full Text] [Related]
17. Intratracheal Administration of Budesonide-Surfactant in Prevention of Bronchopulmonary Dysplasia in Very Low Birth Weight Infants: A Systematic Review and Meta-Analysis. Venkataraman R; Kamaluddeen M; Hasan SU; Robertson HL; Lodha A Pediatr Pulmonol; 2017 Jul; 52(7):968-975. PubMed ID: 28165675 [TBL] [Abstract][Full Text] [Related]
18. Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome. Fujii AM; Patel SM; Allen R; Doros G; Guo CY; Testa S J Perinatol; 2010 Oct; 30(10):665-70. PubMed ID: 20336076 [TBL] [Abstract][Full Text] [Related]
19. The short-term outcome of a large cohort of very preterm infants treated with poractant alfa (Curosurf) for respiratory distress syndrome. A postmarketing phase IV study. Lamboley-Gilmert G; Lacaze-Masmonteil T; Paediatr Drugs; 2003; 5(9):639-45. PubMed ID: 12956620 [TBL] [Abstract][Full Text] [Related]